GlassScriptPhysician profile
David S Pomerantz
NPI 1972529832
$25,213.55
in general payments reported to CMS, 2019-2025
41 companies · $4,309 in 2025
The $4,309 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,957 · 2020: $2,545 · 2021: $3,063 · 2022: $3,410 · 2023: $4,583 · 2024: $4,346 · 2025: $4,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,963.97 |
| Education | $274.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,499.95 | 2019-2025 | |
| Janssen Biotech, INC. | $2,832.13 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $2,270.67 | 2019-2025 | |
| Leo Pharma INC. | $2,195.60 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,629.45 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $1,623.67 | 2019-2025 | Otezla, Otezla, Enbrel |
| Pfizer INC. | $1,337.75 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,125.85 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Ucb, INC. | $1,007.70 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $947.43 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $903.71 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $861.16 | 2019-2025 | Siliq, Cabtreo, Targretin |
| Genzyme Corporation | $827.43 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $602.77 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $473.88 | 2022-2024 | Vtama |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pomerantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.